Molecular Cancer Therapeutics: 13 (3)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther March 1 2014 13 (3) 555-555;

Hypothesis/Commentary

Hypothesis/Commentary

Advances in the Diagnosis and Treatment of Non–Small Cell Lung Cancer

Rathi N. Pillai and Suresh S. Ramalingam

Mol Cancer Ther March 1 2014 13 (3) 557-564; DOI:10.1158/1535-7163.MCT-13-0669

Small Molecule Therapeutics

Small Molecule Therapeutics

A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

Fardokht Abulwerdi, Chenzhong Liao, Meilan Liu, Asfar S. Azmi, Amro Aboukameel, Ahmed S.A. Mady, Thippeswamy Gulappa, Tomasz Cierpicki, Scott Owens, Tao Zhang, Duxin Sun, Jeanne A. Stuckey, Ramzi M. Mohammad and Zaneta Nikolovska-Coleska

Mol Cancer Ther March 1 2014 13 (3) 565-575; DOI:10.1158/1535-7163.MCT-12-0767
Small Molecule Therapeutics | AuthorChoice

Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer

Cleo E. Rolle, Rajani Kanteti, Mosmi Surati, Suvobroto Nandi, Immanuel Dhanasingh, Soheil Yala, Maria Tretiakova, Qudsia Arif, Todd Hembrough, Toni M. Brand, Deric L. Wheeler, Aliya N. Husain, Everett E. Vokes, Ajit Bharti and Ravi Salgia

Mol Cancer Ther March 1 2014 13 (3) 576-584; DOI:10.1158/1535-7163.MCT-13-0109
Small Molecule Therapeutics

The Fatty Acid Synthase Inhibitor Orlistat Reduces the Growth and Metastasis of Orthotopic Tongue Oral Squamous Cell Carcinomas

Michelle Agostini, Luciana Y. Almeida, Débora C. Bastos, Rose M. Ortega, Fernanda S. Moreira, Fabiana Seguin, Karina G. Zecchin, Helena F. Raposo, Helena C.F. Oliveira, Nivea D. Amoêdo, Tuula Salo, Ricardo D. Coletta and Edgard Graner

Mol Cancer Ther March 1 2014 13 (3) 585-595; DOI:10.1158/1535-7163.MCT-12-1136
Small Molecule Therapeutics

The AMPK Inhibitor Compound C Is a Potent AMPK-Independent Antiglioma Agent

Xiaona Liu, Rishi Raj Chhipa, Ichiro Nakano and Biplab Dasgupta

Mol Cancer Ther March 1 2014 13 (3) 596-605; DOI:10.1158/1535-7163.MCT-13-0579
Small Molecule Therapeutics

Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer

Shuo You, Rui Li, Dongkyoo Park, Maohua Xie, Gabriel L. Sica, Ya Cao, Zhi-Qiang Xiao and Xingming Deng

Mol Cancer Ther March 1 2014 13 (3) 606-616; DOI:10.1158/1535-7163.MCT-13-0608
Small Molecule Therapeutics

TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers

Jing Nan, Yuping Du, Xing Chen, Qifeng Bai, Yuxin Wang, Xinxin Zhang, Ning Zhu, Jing Zhang, Jianwen Hou, Qin Wang and Jinbo Yang

Mol Cancer Ther March 1 2014 13 (3) 617-629; DOI:10.1158/1535-7163.MCT-13-0464
Small Molecule Therapeutics

Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α

Tian-Yu Cai, Xiao-Wen Liu, Hong Zhu, Ji Cao, Jun Zhang, Ling Ding, Jian-Shu Lou, Qiao-Jun He and Bo Yang

Mol Cancer Ther March 1 2014 13 (3) 630-642; DOI:10.1158/1535-7163.MCT-13-0490

Large Molecule Therapeutics

Large Molecule Therapeutics

Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity

Haizhen Wang, Jennifer S. Davis and Xiangwei Wu

Mol Cancer Ther March 1 2014 13 (3) 643-650; DOI:10.1158/1535-7163.MCT-13-0645
Large Molecule Therapeutics

Enhancement of the Tumor Penetration of Monoclonal Antibody by Fusion of a Neuropilin-Targeting Peptide Improves the Antitumor Efficacy

Tae-Hwan Shin, Eun-Sil Sung, Ye-Jin Kim, Ki-Su Kim, Se-Ho Kim, Seok-Ki Kim, Young-Don Lee and Yong-Sung Kim

Mol Cancer Ther March 1 2014 13 (3) 651-661; DOI:10.1158/1535-7163.MCT-13-0748

Cancer Biology and Signal Transduction

Cancer Biology and Signal Transduction

Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism

Tri K. Nguyen and Steven Grant

Mol Cancer Ther March 1 2014 13 (3) 662-674; DOI:10.1158/1535-7163.MCT-13-0714
Cancer Biology and Signal Transduction

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

Yan Cheng, Michael P. Holloway, Kevin Nguyen, Dilara McCauley, Yosef Landesman, Michael G. Kauffman, Sharon Shacham and Rachel A. Altura

Mol Cancer Ther March 1 2014 13 (3) 675-686; DOI:10.1158/1535-7163.MCT-13-0416
Cancer Biology and Signal Transduction

CBP-Mediated FOXO-1 Acetylation Inhibits Pancreatic Tumor Growth by Targeting SirT

Kartick C. Pramanik, Neel M. Fofaria, Parul Gupta and Sanjay K. Srivastava

Mol Cancer Ther March 1 2014 13 (3) 687-698; DOI:10.1158/1535-7163.MCT-13-0863
Cancer Biology and Signal Transduction | AuthorChoice

Synuclein γ Compromises Spindle Assembly Checkpoint and Renders Resistance to Antimicrotubule Drugs

Suyu Miao, Kejin Wu, Bo Zhang, Ziyi Weng, Mingjie Zhu, Yunshu Lu, Ramadas Krishna and Yuenian Eric Shi

Mol Cancer Ther March 1 2014 13 (3) 699-713; DOI:10.1158/1535-7163.MCT-13-0671
Cancer Biology and Signal Transduction

Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10–Mediated Paclitaxel Resistance: A Preclinical Study

Rishil J. Kathawala, Kamlesh Sodani, Kang Chen, Atish Patel, Alaa H. Abuznait, Nagaraju Anreddy, Yue-Li Sun, Amal Kaddoumi, Charles R. Ashby Jr and Zhe-Sheng Chen

Mol Cancer Ther March 1 2014 13 (3) 714-723; DOI:10.1158/1535-7163.MCT-13-0743
Cancer Biology and Signal Transduction | AuthorChoice

Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition

Melanie L. Bailey, Nigel J. O'Neil, Derek M. van Pel, David A. Solomon, Todd Waldman and Philip Hieter

Mol Cancer Ther March 1 2014 13 (3) 724-732; DOI:10.1158/1535-7163.MCT-13-0749
Cancer Biology and Signal Transduction

Mutant Ras Elevates Dependence on Serum Lipids and Creates a Synthetic Lethality for Rapamycin

Darin Salloum, Suman Mukhopadhyay, Kaity Tung, Aleksandra Polonetskaya and David A. Foster

Mol Cancer Ther March 1 2014 13 (3) 733-741; DOI:10.1158/1535-7163.MCT-13-0762
Cancer Biology and Signal Transduction

microRNAs miR-27a and miR-27b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites

Steven M. Offer, Gabriel L. Butterfield, Calvin R. Jerde, Croix C. Fossum, Natalie J. Wegner and Robert B. Diasio

Mol Cancer Ther March 1 2014 13 (3) 742-751; DOI:10.1158/1535-7163.MCT-13-0878

Tools and Technologies

Tools and Technologies | AuthorChoice

Cancer-Associated CD43 Glycoforms as Target of Immunotherapy

Franca Maria Tuccillo, Camillo Palmieri, Giuseppe Fiume, Annamaria de Laurentiis, Marco Schiavone, Cristina Falcone, Enrico Iaccino, Ricciarda Galandrini, Cristina Capuano, Angela Santoni, Francesco Paolo D'Armiento, Claudio Arra, Antonio Barbieri, Fabrizio Dal Piaz, David Venzon, Patrizia Bonelli, Franco Maria Buonaguro, Iris Scala, Massimo Mallardo, Ileana Quinto and Giuseppe Scala

Mol Cancer Ther March 1 2014 13 (3) 752-762; DOI:10.1158/1535-7163.MCT-13-0651

Letters to the Editor

Letters to the Editor

Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Letter

Malcolm A. Smith

Mol Cancer Ther March 1 2014 13 (3) 763-763; DOI:10.1158/1535-7163.MCT-13-0968
Letters to the Editor

Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Response

Céline Gongora

Mol Cancer Ther March 1 2014 13 (3) 764-764; DOI:10.1158/1535-7163.MCT-13-1026

Main menu

User menu

Search

Table of Contents

Highlights

Hypothesis/Commentary

Small Molecule Therapeutics

Large Molecule Therapeutics

Cancer Biology and Signal Transduction

Tools and Technologies

Letters to the Editor

Issue Highlights

Jump to

Articles

Info for

About MCT